Bruker shares down 40 percent since January as weak results reshape outlook. The analytical life sciences company reported organic sales declined 4 percent in 2025 while carrying high leverage around 3 times debt-to-EBITDA. Management guidance for 2026 projects modest 4 to 5 percent total sales growth with just 1 to 2 percent organic expansion and adjusted earnings per share between 2.10 and 2.15 dollars. This guidance implies a valuation compression to 15 to 16 times forward earnings from elevated prior multiples. Significant M&A activity raises questions about capital allocation priorities during a challenging revenue environment. While execution concerns persist and conviction remains low, improving risk-reward dynamics at current depressed valuations could warrant consideration of small speculative positions on further weakness.
Post from MarketNews_en
Log in to interact with content.